DarioHealth (DRIO) Research & Development (2012 - 2026)

DarioHealth (DRIO) has reported Research & Development for 15 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 43.56% year-over-year to $2.1 million; the trailing twelve-month figure through Jun 2026 stood at $10.4 million (down 43.7% YoY), and the FY2025 full-year result was $13.8 million, down 42.96% from the prior year.
• Research & Development eased to $2.1 million in Q2 2026 per DRIO's latest filing, from $2.4 million in the prior quarter.
• Across five years, Research & Development topped out at $6.8 million in Q2 2024 and bottomed at $2.1 million in Q2 2026.
• Historically, Research & Development has averaged $4.6 million across 5 years, with a median of $4.8 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 123.24% in 2022, then plunged 50.12% in 2025.
• Over 5 years, Research & Development stood at $4.8 million in 2022, then slipped by 12.25% to $4.2 million in 2023, then rose by 25.86% to $5.3 million in 2024, then slumped by 50.12% to $2.6 million in 2025, then retreated by 20.27% to $2.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.1 million, $2.4 million, and $2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.